Literature DB >> 1946838

Stability of resting deoxyglucose metabolic values in PET studies of schizophrenia.

E J Bartlett1, F Barouche, J D Brodie, A Wolkin, B Angrist, J Rotrosen, A P Wolf.   

Abstract

Positron emission tomography (PET) and the deoxyglucose method were used to determine the test-retest stability of regional cerebral glucose metabolism in 8 male schizophrenic patients and 11 normal control subjects, scanned twice under baseline (resting) conditions. Normal and schizophrenic subjects showed comparable stability of regional metabolism. When the regional values were scaled to compensate for the effects of changes in whole brain metabolism, the resulting mean regional changes were reduced to about 1-2% in both groups. This study demonstrates that the baseline resting state is an appropriate reference state for schizophrenic subjects in deoxyglucose PET experiments.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1946838     DOI: 10.1016/0925-4927(91)90025-l

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  3 in total

1.  Six-month test-retest reliability of MRI-defined PET measures of regional cerebral glucose metabolic rate in selected subcortical structures.

Authors:  S M Schaefer; H C Abercrombie; K A Lindgren; C L Larson; R T Ward; T R Oakes; J E Holden; S B Perlman; P A Turski; R J Davidson
Journal:  Hum Brain Mapp       Date:  2000-05       Impact factor: 5.038

2.  Toward a neuroimaging treatment selection biomarker for major depressive disorder.

Authors:  Callie L McGrath; Mary E Kelley; Paul E Holtzheimer; Boadie W Dunlop; W Edward Craighead; Alexandre R Franco; R Cameron Craddock; Helen S Mayberg
Journal:  JAMA Psychiatry       Date:  2013-08       Impact factor: 21.596

3.  Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of Amphetamine.

Authors:  Kyung-Heup Ahn; Andrew Sewell; Jacqueline Elander; Brian Pittman; Mohini Ranganathan; Handan Gunduz-Bruce; John Krystal; Deepak Cyril D'Souza
Journal:  Neuropsychopharmacology       Date:  2015-05-08       Impact factor: 7.853

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.